Yet Another Glaucoma Drug and RP

Below is some information on yet another glaucoma drug that has some result in RP. Keep in mind the drug in this study was delivered topically. So, in actuality, it is a relatively small amount of medication that actually makes it to the target area.

If you check out http://www.clinicaltrials.gov/ and enter "retinitis pigmentosa", look for the clinical trial for the "Brimonidine Tartrate Implant". Brimonidine is a glaucoma drug. You will see the drug manufacturer, Allergan, has invested the research and development dollars to create a retinal drug delivery system in the form of an implant. The drug of choice has traditionally been used for glaucoma.This study is going to take place in Europe.

I find this of particular interest given the acetazolamide (another glaucoma drug) case study from the University of London. No one has ever accurately replicated that woman's experience in the form of a larger scale pilot study. In the one attempt, the dosing was incorrect and the study was prematurely terminated.

Now, another glaucoma drug is emerging and a company has invested major funds in an implant in order to deliver it directly to the retinas of RPers.

Interesting....

Below is a link to a pilot study done in Israel. Its results will not enthrall, but keep in mind this is eye drops, not even a systemic delivery in the form of an oral pill.

http://www.liebertonline.com/doi/abs/10.1089/jop.2007.0022